Home / Investor / Press Release / Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222 (16 Aug 2022)
Home ⁄ Press Release ⁄ Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222 (16 Aug 2022)
Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222 (16 Aug 2022)